Pulmonary Administration of TLR2/6 Agonist after Allergic Sensitization Inhibits Airway Hyper-Responsiveness and Recruits Natural Killer Cells in Lung Parenchyma.

Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE

Original Publication: Basel, Switzerland : MDPI, [2000-

Killer Cells, Natural*/immunology ; Killer Cells, Natural*/drug effects ; Toll-Like Receptor 2*/agonists ; Toll-Like Receptor 2*/metabolism ; Lung*/pathology ; Lung*/immunology ; Lung*/drug effects ; Ovalbumin* ; Asthma*/drug therapy ; Asthma*/immunology ; Asthma*/pathology ; Toll-Like Receptor 6*/agonists; Animals ; Mice ; Mice, Inbred BALB C ; Female ; Disease Models, Animal ; Hypersensitivity/drug therapy ; Hypersensitivity/immunology ; Bronchial Hyperreactivity/drug therapy ; Bronchial Hyperreactivity/immunology ; Bronchoalveolar Lavage Fluid ; Diglycerides ; Oligopeptides

Asthma is a chronic lung disease with persistent airway inflammation, bronchial hyper-reactivity, mucus overproduction, and airway remodeling. Antagonizing T2 responses by triggering the immune system with microbial components such as Toll-like receptors (TLRs) has been suggested as a therapeutic concept for allergic asthma. The aim of this study was to evaluate the effect of a TLR2/6 agonist, FSL-1 (Pam2CGDPKHPKSF), administered by intranasal instillation after an allergic airway reaction was established in the ovalbumin (OVA) mouse model and to analyze the role of natural killer (NK) cells in this effect. We showed that FSL-1 decreased established OVA-induced airway hyper-responsiveness and eosinophilic inflammation but did not reduce the T2 or T17 response. FSL-1 increased the recruitment and activation of NK cells in the lung parenchyma and modified the repartition of NK cell subsets in lung compartments. Finally, the transfer or depletion of NK cells did not modify airway hyper-responsiveness and eosinophilia after OVA and/or FSL-1 treatment. Thus, the administration of FSL-1 reduces airway hyper-responsiveness and bronchoalveolar lavage eosinophilia. However, despite modifications of their functions following OVA sensitization, NK cells play no role in OVA-induced asthma and its inhibition by FSL-1. Therefore, the significance of NK cell functions and localization in the airways remains to be unraveled in asthma.

J Allergy Clin Immunol. 2017 Apr;139(4):1321-1330.e4. (PMID: 27670241)
FEMS Immunol Med Microbiol. 2006 Oct;48(1):44-55. (PMID: 16965351)
Curr Opin Allergy Clin Immunol. 2017 Feb;17(1):50-54. (PMID: 27841766)
Am J Respir Crit Care Med. 2005 Sep 1;172(5):566-72. (PMID: 15901606)
Scand J Immunol. 2010 Aug;72(2):118-27. (PMID: 20618770)
Eur J Immunol. 2021 Oct;51(10):2387-2398. (PMID: 34415577)
PLoS One. 2013;8(2):e55307. (PMID: 23393567)
Immunology. 2022 Sep;167(1):28-39. (PMID: 35751452)
Int Immunol. 2008 Sep;20(9):1155-67. (PMID: 18596023)
Immunol Res. 2014 Jan;58(1):28-39. (PMID: 24132552)
Sci Transl Med. 2013 Feb 27;5(174):174ra26. (PMID: 23447017)
J Asthma Allergy. 2023 Apr 08;16:367-382. (PMID: 37063243)
Front Immunol. 2020 Feb 25;11:144. (PMID: 32161582)
EMBO Mol Med. 2018 Apr;10(4):. (PMID: 29444897)
Sci Immunol. 2017 Mar 10;2(9):. (PMID: 28783702)
J Allergy Clin Immunol. 2004 Mar;113(3):482-8. (PMID: 15007351)
Proc Natl Acad Sci U S A. 2011 Nov 8;108(45):18324-9. (PMID: 22021440)
Front Immunol. 2021 Mar 16;12:635935. (PMID: 33796103)
Cell. 2021 Mar 18;184(6):1469-1485. (PMID: 33711259)
J Allergy Clin Immunol Pract. 2021 Mar;9(3):1267-1275. (PMID: 33039645)
Cancers (Basel). 2021 Aug 24;13(17):. (PMID: 34503073)
Arch Med Res. 2017 Nov;48(8):717-726. (PMID: 29224909)
Allergy. 2003 Jan;58(1):67-71. (PMID: 12580810)
Medicine (Baltimore). 2017 May;96(20):e6822. (PMID: 28514297)
Nat Rev Immunol. 2013 Jun;13(6):453-60. (PMID: 23681101)
J Immunol. 2005 Jun 15;174(12):7558-63. (PMID: 15944255)
J Allergy Clin Immunol. 2005 Apr;115(4):841-7. (PMID: 15806008)
Immunol Cell Biol. 2014 Mar;92(3):256-62. (PMID: 24366517)
J Immunol. 2008 Apr 1;180(7):4742-53. (PMID: 18354198)
Inflamm Res. 2008 Aug;57(8):379-87. (PMID: 18787777)
J Clin Invest. 2011 Nov;121(11):4420-32. (PMID: 22005301)
J Allergy Clin Immunol. 2008 Feb;121(2):479-85. (PMID: 18061653)
Eur Respir J. 2020 May 14;55(5):. (PMID: 32108047)
PLoS One. 2010 Sep 02;5(9):. (PMID: 20824059)
Medicine (Baltimore). 2017 Sep;96(35):e7909. (PMID: 28858111)
J Immunol. 2004 Mar 1;172(5):2739-43. (PMID: 14978071)
Int Arch Allergy Immunol. 2010;152(2):131-9. (PMID: 20016195)
Immunology. 2009 Oct;128(2):151-63. (PMID: 19740372)
J Immunol Res. 2020 Jan 4;2020:2045860. (PMID: 32377528)
Pulm Pharmacol Ther. 2011 Apr;24(2):203-14. (PMID: 21195789)
Front Immunol. 2018 May 15;9:1027. (PMID: 29867994)
Nature. 2024 Feb;626(8000):727-736. (PMID: 38383621)
Am J Respir Cell Mol Biol. 2005 Mar;32(3):218-24. (PMID: 15576672)
J Allergy Clin Immunol. 2008 Jul;122(1):86-92, 92.e1-8. (PMID: 18547625)
Int J Mol Sci. 2021 Apr 09;22(8):. (PMID: 33918621)
PLoS Pathog. 2010 Mar 12;6(3):e1000811. (PMID: 20300608)
Front Allergy. 2022 Nov 24;3:1051368. (PMID: 36506644)
Eur Respir Rev. 2023 Jul 12;32(169):. (PMID: 37437915)
Blood. 2009 May 28;113(22):5488-96. (PMID: 19234143)
Blood. 2013 Jun 6;121(23):4663-71. (PMID: 23580661)
J Vis Exp. 2013 May 15;(75):e50172. (PMID: 23711876)
Immunol Rev. 2007 Dec;220:169-82. (PMID: 17979846)
Cancer Immunol Immunother. 2015 Sep;64(9):1175-84. (PMID: 26036909)
J Immunol Methods. 2012 Jan 31;375(1-2):100-10. (PMID: 21996427)

2006-SEST-031-01 Agence Nationale de la Recherche; U1019 Inserm

Keywords: Toll-like receptor-2; allergic asthma; natural killer cell

0 (Toll-Like Receptor 2)
9006-59-1 (Ovalbumin)
0 (Toll-Like Receptor 6)
0 (FSL-1 lipoprotein, synthetic)
0 (Tlr2 protein, mouse)
0 (Tlr6 protein, mouse)
0 (Diglycerides)
0 (Oligopeptides)

Date Created: 20240914 Date Completed: 20240914 Latest Revision: 20241105

20241105

PMC11394962

10.3390/ijms25179606

39273551